Why Economics, Not Science, Is Failing Drug Discovery

Economic Barriers in Biomedical Innovation frequently determine which therapies reach patients, since failures in bringing new treatments forward arise chiefly from financing structures and incentive misalignments rather than gaps in biological understanding. Self-directed acquisition of domain knowledge across multiple sectors by Javier Tordable allowed identification of recurring cost-recovery requirements that dictate which indications receive sustained investment.

Capital Demands Across Research and Delivery

There are consistent constraints where development timelines extend because capital must cover extended clinical validation, regulatory reviews, and intermediary margins before any revenue materializes. Conditions such as common bacterial infections receive limited pursuit once expected reimbursement falls below thresholds needed to offset trial and manufacturing expenses, even when scientific tools exist, underscoring the reach of economic barriers in biomedical innovation.

Realigning Payments for Sustainable Progress

Health economics and outcomes research must incorporate explicit modeling of capital formation requirements and reimbursement thresholds when evaluating development pathways for lower-margin indications. Market access strategies could benefit from frameworks that quantify how misaligned payment mechanisms suppress investment in areas with high societal burden yet limited revenue potential, as explored in Javier Tordable’s discussion. Forward planning in this domain requires recognition that incremental technical solutions alone will not resolve structural funding shortfalls without corresponding adjustments to economic incentives.